Denali Therapeutics Inc. DNLI Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s business segments — operating income (loss)?
- Denali Therapeutics Inc. (DNLI) reported business segments — operating income (loss) of -$137.36M in Q1 2026.
- How has Denali Therapeutics Inc.'s business segments — operating income (loss) changed year-over-year?
- Denali Therapeutics Inc.'s business segments — operating income (loss) increased by 5.6% year-over-year, from -$145.58M to -$137.36M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — operating income (loss) has grown at a 17.7% compound annual growth rate (CAGR), from -$340.74M to -$555.34M.
- What does business segments — operating income (loss) mean?
- Calculated as total segment revenue minus total operating expenses, representing the profitability of the core business operations. For early-stage biotechnology companies, this is typically a loss, reflecting heavy investment in pipeline development. It serves as a primary indicator of the company's progress toward commercial viability.